Andrea Lobo, PhD,  science writer—

In adults with cystic fibrosis (CF), six of months treatment with Kaftrio (elexacaftor/tezacaftor/ivacaftor) led to lower levels of biomarkers of inflammation, but higher blood levels of fat-like molecules considered to be cardiovascular risk factors, according to a recent study in Italy. While highly effective, the triple-combination therapy — available…

Oransi has donated air purifiers to help people with cystic fibrosis (CF) affected by smoke-filled air from the wildfires that flared up last month in Southern California, Claire’s Place Foundation said. The foundation’s financial assistance program provides CF patients and their families with one-time funds for air purifiers,…

Clarametyx Biosciences has announced an investment from Kineticos AMR Accelerator (KAMRA) Fund to support the development of CMTX-101, a non-antibiotic treatment candidate for persistent bacterial lung infections in people with cystic fibrosis (CF). This investment, which extends the company’s $33-million financing completed last year, will contribute…

People with cystic fibrosis (CF) saw sustained reductions in the use of several other CF therapies after two years of treatment with Kaftrio (elexacaftor/tezacaftor/ivacaftor), with airway medications and antibiotics being the most reduced, according to a real-world study from Denmark. “This study adds evidence of the real-world impact…

A Phase 1b trial assessing the safety of RCT2100, Recode Therapeutics’ inhaled therapy candidate for people with cystic fibrosis (CF), has now dosed its first patient in the U.S. The trial already was underway in Europe. RCT2100 is being developed for patients who do not respond to or…

A cystic fibrosis (CF) therapy slightly but significantly increased diversity in the lung microbiome, the community of microorganisms found in the lungs, in adolescents with the disease, a study in Switzerland found. Treatment with Trikafta was specifically linked to an increase in commensal bacteria, those commonly present in healthy…

A clinical trial assessing the safety and tolerability of CMTX-101, an antibody-based therapy for cystic fibrosis (CF) lung infections, has started its second part. Phase 2a of the Phase 1b/2a trial (NCT06159725) aims to enroll up to 41 adults with CF at several sites in the U.S., treatment developer…

The abundance of Pseudomonas bacteria and related virulence factors in the lungs of people with cystic fibrosis (CF) after a transplant may raise their risk of a progressive decline in lung function and organ rejection, according to a recent study. Virulence is the ability of a microorganism to cause…

The 10th Annual Glow Ride for Cystic Fibrosis (CF), held Sept. 21 at Hermosa Beach, California, exceeded expectations by raising more than $65,700 to support families experiencing financial difficulties due to extended hospital stays. That’s according to Claire’s Place Foundation, a nonprofit that provides support to children with…

An agency of the National Institutes of Health has awarded funding up to $7 million to researchers at the University of California (UC) to study the use of probiotics to treat lung infections in people with cystic fibrosis (CF). The funding comes from the Advanced Research Projects Agency…